Latanoprost: Structure, Properties, Pharmacology, and Safety

Kapil Radadiya
Written by Kapil Radadiya
Latanoprost: Structure, Properties, Pharmacology, and Safety

Latanoprost, a synthetic prostaglandin F2α analogue, helps reduce elevated intraocular pressure (IOP) through its use in ophthalmic medicines. It treats open-angle glaucoma and ocular hypertension by lowering eye pressure, helping protect vision and reducing the risk of further optic nerve damage.

What makes Latanoprost particularly useful is its mechanism of action. Rather than reducing the production of fluid inside the eye, it primarily helps aqueous humour drain more effectively.

Beyond its clinical applications, Latanoprost has distinct chemical and physical characteristics that influence its formulation, stability and pharmaceutical handling.

This article examines the chemical structure, properties, pharmacology, therapeutic uses and safety considerations of Latanoprost, with a distinction between the active pharmaceutical ingredient (API) and finished ophthalmic medicines.

1. Chemical Structure of Latanoprost

Latanoprost is a synthetic analogue of prostaglandin F2α. Its molecular structure includes a cyclopentane ring, hydroxyl groups, a phenyl-substituted side chain and an isopropyl ester group.

The ester group is particularly important to its pharmacological behaviour.

Healthcare professionals administer Latanoprost in its prodrug form. After topical application to the eye, enzymes in the cornea convert it into Latanoprost acid, the biologically active form responsible for its pressure-lowering effect.

2D Structure

The two-dimensional structure illustrates the arrangement of atoms, functional groups and stereochemical features of Latanoprost.

These structural details are relevant to its physicochemical properties and its conversion into the active acid after administration.

Two-dimensional (2D) chemical structure of Latanoprost (CAS No. 130209-82-4), showing its molecular arrangement and functional groups.

3D Structure

A three-dimensional representation helps illustrate the spatial arrangement of the molecule.

Molecular geometry is important when studying drug–receptor interactions. However, a structural illustration alone does not establish receptor-binding affinity or clinical effectiveness.

Three-dimensional (3D) molecular structure of Latanoprost, illustrating the spatial arrangement of its atoms and molecular geometry.

2. Latanoprost Names and Chemical Identifiers

Accurate chemical identifiers are important for pharmaceutical development, analytical documentation and raw-material procurement.

Latanoprost is identified by its chemical name, molecular formula, molecular weight and CAS Registry Number.

PropertyDetails
Chemical nameLatanoprost
Chemical classSynthetic prostaglandin F2α analogue
Molecular formulaC₂₆H₄₀O₅
Molecular weight432.59 g/mol
CAS number130209-82-4
Pharmacological classificationProstaglandin analogue
Active metaboliteLatanoprost acid
Primary therapeutic applicationReduction of elevated intraocular pressure

Ophthalmic medicines marketed under brand names such as Xalatan and Monoprost contain Latanoprost as their active ingredient in relevant markets.

These are medicinal product names rather than alternative chemical names for the API.

For pharmaceutical sourcing, buyers should confirm the CAS number, chemical identity and applicable specification before purchasing Latanoprost API.

3. Chemical and Physical Properties of Latanoprost

The physicochemical characteristics of Latanoprost are relevant to ophthalmic formulation development, analytical testing and storage.

Its molecular structure gives it lipophilic characteristics, while its ester functionality contributes to its behavior as a prodrug.

PropertyDescription
Molecular formulaC₂₆H₄₀O₅
Molecular weight432.59 g/mol
CAS number130209-82-4
Chemical classProstaglandin F2α analogue
Water solubilityLimited aqueous solubility
Organic solvent solubilitySoluble in suitable organic solvents, including ethanol
LipophilicityLipophilic compound
Chemical functionalityIsopropyl ester and hydroxyl groups

4. Latanoprost Drug and Medication Information

Latanoprost is primarily used in prescription ophthalmic medicines intended to reduce elevated intraocular pressure.

Ophthalmic Formulation

A commonly marketed formulation is Latanoprost ophthalmic solution 0.005%, equivalent to 50 micrograms per millilitre.

The finished medicine contains Latanoprost as the active ingredient alongside formulation-specific excipients.

Formulation composition, preservatives, packaging and storage instructions can differ between authorised products.

Mechanism of Action

Enzymes in the cornea convert Latanoprost into its active acid form.

The active metabolite acts through prostaglandin FP receptors and reduces intraocular pressure mainly by increasing uveoscleral outflow of aqueous humour.

Aqueous humour is the fluid that circulates within the front part of the eye. When its drainage is insufficient, intraocular pressure can rise.

By improving fluid outflow, Latanoprost helps reduce this pressure.

Dosage and Administration

For many approved 0.005% ophthalmic solutions, the recommended dosage is one drop in the affected eye or eyes once daily, usually in the evening.

Healthcare professionals recommend avoiding more frequent administration because it may reduce the pressure-lowering effect.

Patients should follow the instructions supplied with their prescribed medicine and the advice of their ophthalmologist.

These dosage instructions apply to authorised finished ophthalmic products, not to bulk Latanoprost API.

5. Pharmacology and Biochemistry of Latanoprost

To understand Latanoprost pharmacology, we examine how the body absorbs, activates, distributes and eliminates the drug.

Pharmacokinetics

Absorption and activation

After topical administration, Latanoprost passes through the cornea, where esterases hydrolyse the parent compound to Latanoprost acid.

This conversion produces the biologically active form.

Distribution

transiently in systemic circulation. write in active vocie

The active acid reaches the aqueous humour, and laboratory tests can also detect it briefly in systemic circulation.

Following topical administration, systemic exposure is relatively brief.

Metabolism

The liver primarily metabolises Latanoprost acid that reaches systemic circulation through fatty acid beta-oxidation pathways.

Elimination

The plasma elimination half-life of Latanoprost acid is approximately 17 minutes.

The kidneys eliminate most of its metabolites.

Do not confuse this short plasma half-life with the duration of the medicine’s effect on intraocular pressure.

Pharmacodynamics

The pressure-lowering effect of Latanoprost generally begins around three to four hours after administration.

Maximum reduction in intraocular pressure is typically observed after approximately eight to twelve hours.

The effect can persist for at least 24 hours, supporting once-daily administration.

Individual responses may vary, and treatment effectiveness should be monitored by an eye-care professional.

Explore a leading manufacturer of APIs.

With over 10 years of expertise, we ensure GMP compliance and provide reliable, high-quality solutions.

6. Therapeutic Uses of Latanoprost

Open-Angle Glaucoma

Open-angle glaucoma is a condition associated with progressive optic nerve damage.

Elevated intraocular pressure is an important modifiable risk factor.

Latanoprost helps lower pressure and is commonly used as part of glaucoma management.

Although reducing intraocular pressure can help limit the risk of further damage, the medicine does not reverse established optic nerve injury.

Ocular Hypertension

Ocular hypertension refers to elevated pressure inside the eye without necessarily having detectable glaucomatous optic nerve damage.

Treatment decisions depend on the patient’s overall risk of developing glaucoma.

Latanoprost may be prescribed when an ophthalmologist considers pressure reduction appropriate.

Clinical Benefits

Latanoprost has several established therapeutic characteristics:

  • Effective reduction of elevated intraocular pressure.
  • Once-daily administration for commonly approved formulations.
  • Sustained pressure-lowering activity.
  • An established role in glaucoma and ocular hypertension treatment.

Its suitability depends on the individual patient’s condition, medical history and response to treatment.

7. Latanoprost Side Effects and Safety Considerations

Like other prescription medicines, Latanoprost can cause adverse reactions.

Most reported effects involve the eye or surrounding tissues, although more serious complications can occur in susceptible patients.

Common Side Effects

Possible adverse effects include:

  • Eye redness or conjunctival hyperaemia.
  • Ocular irritation, burning or stinging.
  • Changes in eyelash length, thickness or pigmentation.
  • Darkening of the skin around the eyelids.
  • Increased brown pigmentation of the iris.

Iris pigmentation changes may be permanent. Eyelash and periocular skin changes may be reversible in some patients after treatment is discontinued.

Important Warnings and Precautions

Macular oedema

Macular oedema, including cystoid macular oedema, has been reported during treatment. Caution is particularly important in patients with relevant ocular risk factors.

Ocular inflammation

Latanoprost should be used cautiously in patients with a history of intraocular inflammation where the prescribing information advises caution.

Herpetic keratitis

Latanoprost has been associated with reactivation of herpes simplex keratitis. Relevant precautions should be followed.

Hypersensitivity

Patients with known hypersensitivity to Latanoprost or other ingredients in a particular finished formulation should not use that product.

Pregnancy and breastfeeding

Use during pregnancy or breastfeeding requires an individual clinical assessment based on the applicable prescribing information.

Patients experiencing significant eye pain, sudden vision changes or other concerning symptoms should seek prompt medical assessment.

8. Latanoprost API Safety and Handling

Bulk Latanoprost API and finished ophthalmic medicines have different handling requirements.

The safety information provided with a finished eye-drop product should not be applied to the handling of raw Latanoprost API.

Chemical Safety

Personnel handling Latanoprost API should follow the current Safety Data Sheet, approved workplace procedures and appropriate exposure-control measures.

Relevant precautions may include controlled handling, suitable protective equipment, prevention of accidental exposure and appropriate containment during weighing or transfer.

Use an occupational risk assessment to determine the required controls.

Storage and Stability

Latanoprost API storage conditions must follow the manufacturer’s approved stability data, product specification and handling instructions.

Light exposure, temperature and packaging suitability may be relevant to maintaining product quality.

Storage requirements for finished ophthalmic solutions can differ between authorised formulations.

For example, certain approved Latanoprost eye drops require refrigeration before opening and permit limited room-temperature storage after opening. These instructions must not be applied automatically to bulk API.

Environmental and Waste Management

Follow applicable pharmaceutical waste procedures and local regulations when managing Latanoprost-containing waste.

Before disposing of unused API, contaminated packaging or laboratory waste, review the relevant Safety Data Sheet and follow the site’s waste-management requirements.

Assess environmental persistence and ecological safety using supporting scientific data rather than making assumptions.

9. Latanoprost API Quality Considerations

For pharmaceutical manufacturers, the quality of Latanoprost API is an important part of finished-product development and control.

A suitable API specification may address identity, assay, related substances and other relevant quality attributes.

The exact testing programme depends on the applicable specification and regulatory requirements.

Before sourcing material, pharmaceutical buyers should review the available Certificate of Analysis, relevant technical documentation, storage requirements and packaging information.

Chemignition Laboratory provides information about its Latanoprost API for pharmaceutical sourcing enquiries.

Customers can contact the team to discuss applicable product specifications, documentation and supply requirements.

FAQs

IUPAC Name of Latanoprost?

Isopropyl (Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate.

Molecular Formula of Latanoprost?

C26H40O5

Molecular Weight of Latanoprost?

432.59 g/mol

CAS Number of Latanoprost?

130209-82-4

What is Latanoprost used for?

Latanoprost is used to treat:

  • Glaucoma (Open-Angle): Reduces intraocular pressure to prevent optic nerve damage.
  • Ocular Hypertension: Lowers elevated pressure in the eye to reduce the risk of vision loss.
How does Latanoprost work?

Latanoprost increases the outflow of aqueous humor through the uveoscleral pathway, reducing intraocular pressure. It mimics the natural prostaglandin F2α, targeting specific receptors in the eye to improve fluid drainage.

How is Latanoprost administered?

Latanoprost is applied as an eye drop.